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ABSTRACT
There are no studies in Mexico comparing Hepatitis C virus (HCV) epidemiology among 
Health Institutions. In this report, we described the deaths and hospitalizations due to HCV 
in the three main Health Institutions in Mexico: the Mexican Institute of Social Security, 
the Institute of Social Security for State Workers and the Ministry of Health, during the 
period 2004-2017. A secondary analysis was carried out across the country using hospital 
administrative death databases. Adult deaths and hospitalizations rates were calculated in 
reference to the total affiliated population and all-cause in-hospital mortality risk were also 
evaluated. There were 7,914 deaths and 9,002 hospitalizations due to HCV. Mortality and 
hospitalization rates of these three institutions together showed a continuous decrease over 
the analyzed time: the mortality rate dropped from 1.25 to 0.41 per 100,000 affiliates during 
2004 and 2017, respectively (66.9% of change), and the hospitalization rate dropped from 
2.19 to 0.39 per 100,000 affiliates (81.9% of change). All-cause in-hospital survival accounted 
for 89.6%. Older age groups and Ministry of Health hospitalizations were associated with 
higher all-cause in-hospital death rates. In conclusion, the mortality and hospitalizations rates 
found in this study reflect a decrease in the burden of HCV in Mexico.
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INTRODUCTION
Hepatitis C is a blood-transmitted infection caused by the Hepatitis C virus 
(HCV), which can lead to chronic liver disease, cirrhosis, hepatocellular carcinoma 
and death1. Hepatitis C is a global public health problem that affects 71 million 
people worldwide and causes about 400,000 deaths annually2. 
Epidemiological studies in Mexico have estimated a prevalence of HCV infection 
between 0.5% and 1.5%3, however, to our knowledge, there are no studies describing 
hospitalizations and mortality caused by HCV and comparing these outcomes 
among Health Institutions.
In Mexico, above 90% of the population has medical coverage and is served by 
the three main Health Institutions: the Mexican Institute of Social Security (IMSS), 
the Institute of Social Security for State Workers (ISSSTE) and the Ministry of 
Health (MoH), with about 60, 13 and 53 million affiliates, respectively. The first 
two institutions are social security systems bringing health care and socioeconomic 
benefits to formal sector workers as well as government employees and their families. 
In contrast, MoH provides health services to social security unaffiliated Mexicans, 
many of whom have been incorporated to the “Popular Insurance” health program4-7. 
Given the lack of recent reports quantifying the epidemiological burden of 
HCV in our country among Health Institutions, we aimed to describe the deaths 
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and hospitalizations due to HCV, in affiliates to the three 
main Health Institutions in Mexico during a 13-year period 
(2004-2017). In this report, we have also described the 
in-hospital survival in the hospitalizations due to HCV as 
well.
MATERIALS AND METHODS
Study design and population
A national-wide data analysis was carried out using 
death and hospital discharge information from the Mexican 
Epidemiological and Statistical Deaths Subsystem and 
the Hospital Discharge Database System. These database 
systems integrate information from all the health institutions 
annually, providing data from the 32 States that encompass 
the Mexican territory.
HCV registers in adults aged 20 and over in the years 
2004-2017 were identified by using the B17.1, B18.2 and 
B19.2 codes of the International Classification of Diseases, 
10th revision. Those codes corresponded to acute, chronic 
and unspecified viral hepatitis C respectively, and were 
identified as the main cause of death and hospitalization. 
Data on sex, age and geographical region were obtained 
for each register.
Statistical analysis
Characteristics of the deaths and hospitalizations were 
compared in the IMSS, ISSSTE and the MoH groups by 
the chi-square and the one-way ANOVA tests.
Crude and adjusted HCV death and hospitalization rates 
were expressed per 100,000 affiliates aged 20 and over for 
the IMSS, the ISSSTE, the MoH, and for the three Health 
Institutions together. Adjusted rates were standardized using 
the World Health Organization World Standard Population 
2000-20258, in order to control variations in the population 
age distributions among Health Institutions. 
To evaluate all-cause in-hospital survival, we estimated 
survival curves with 95% Confidence Intervals (95% CI) 
by means of the Kaplan-Meier method. We have also 
conducted a multivariate Cox proportional hazard model 
to calculate adjusted hazard ratios (HR) with 95% CI, in 
order to assess the association between hospitalization 
characteristics and all-cause in-hospital mortality risk.
Mortality rates, hospitalization rates and all-cause 
in-hospital survival were estimated by sex, age group, 
health institution (IMSS, ISSSTE and MoH) and 
geographical region. For the last variable, the 32 States 
were grouped into three regions, as follows: West 
(Aguascalientes, Baja California, Baja California Sur, 
Chihuahua, Colima, Durango, Guanajuato, Jalisco, 
Michoacan, Nayarit, Sinaloa and Sonora), Central (Mexico 
City, Hidalgo, Mexico, Morelos, Queretaro and Tlaxcala), 
and East (Campeche, Chiapas, Coahuila, Guerrero, Nuevo 
Leon, Oaxaca, Puebla, Quintana Roo, San Luis Potosi, 
Tabasco, Tamaulipas, Veracruz, Yucatan and Zacatecas). In 
all the analyses, the deaths, hospitalizations and population 
for the MoH corresponded to the Popular Insurance 
affiliates only. The R software v.3.0.1 was used to carry 
out the statistical analysis.
Ethical statement
All the procedures were carried out in accordance 
with ethical standards of the institutional guidelines and 
the national laws, and also according to the 1964 Helsinki 
declaration and its later amendments.
Given that this study was based on the use of public 
available databases with no personal identifiers, neither 
the Institutional Review Board approbation, nor the formal 
informed consent were required.
RESULTS
Deaths due to Hepatitis C virus and mortality rates 
A total of 7,914 deaths due to HCV from 2004-2017 
were included in our study (5,157 from the IMSS, 1,269 
from the ISSSTE and 1,488 from the MoH). The mean 
age at death was 60.4 years old and most deaths occurred 
in females from the West region of Mexico. Significant 
differences regarding sex, age and geographical region 
were observed among Health Institutions (Table 1). The 
20-years-old adult and over affiliated population increased 
in the three health institutions: for IMSS from 28.5 in 2004 
to 47.4 million in 2017; for ISSSTE from 5.8 to 7.6 million 
and for MoH adult affiliates incremented from 2.6 to 
29.1 million (Supplementary Figure 1) in the study period. 
Mortality rates of the three institutions together showed a 
continuous decrease over the time (from 1.25 in 2004 to 
0.41 per 100,000 affiliates in 2017 – a 66.9% of change) 
(Figure 1). This decrease has also been observed in all the 
three Health Institutions, both, in males and females, in each 
of the age groups and in the three geographical regions, as 
well (Supplementary Figure 2).
Hospitalizations due to Hepatitis C virus and 
hospitalization rates
As outlined in Table 2, we included 9,002 hospitalizations 
due to HCV (6,838 in the IMSS, 1,380 in the ISSSTE and 
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784 in the MoH), the average length of hospital stay was 
5.3 days and the mean age at hospitalization was 52.3 years 
old. Similar to death results, most hospitalizations occurred 
in females and in the West region of Mexico, with significant 
differences among Health Institutions.
Hospitalization rates combining the three institutions 
together showed a continuous decrease during the study 
period (from 2.19 in 2004 to 0.39 per 100,000 affiliates in 
2017 – a 81.9% of change) (Figure 2). This rate decrement 
was observed in the IMSS and in the ISSSTE, in both, 
males and females, in all age groups and in the three 
geographical regions. However, an important increment 
in hospitalization rates was found among MoH affiliates 
(Supplementary Figure 3). 
Hepatitis C virus in-hospital survival
In the survival analysis, 966 all-cause in-hospital deaths 
and 47,472 in-hospital person-days were examined. During 
the study period, 10.7% of hospitalizations reported death at 
discharge (overall survival of 89.3%). The Kaplan-Meier’s 
survival analysis and the multivariate Cox proportional 
hazard model, all-cause in-hospital mortality rates were 
significantly higher in older age groups, in the West and East 
regions and in the MoH hospitalizations (Table 3, Figure 3 
and Supplementary Figure 4).
DISCUSSION
HCV is a world-wide public health problem with 
a global prevalence around 1% and important regional 
variations even in different areas of the same country2.
Several studies suggest that HCV incidence and 
Table 1 - Characteristics of the deaths due to hepatitis C virusa.
Characteristic Mexican Institute 
of Social Security
Institute of Social 
Security for State 
Workers
Ministry of 
Health
All the three 
Institutions P-value
b
No. of deaths 5,157 1,269 1,488 7,914
Sex (%)
    Male 32.3 27.4 48.4 34.5
    Female 67.7 72.6 51.6 65.5 <0.001
Age at death, years (mean ± SD) 60.7 ± 12.3 63.4 ± 11.3 56.5 ± 13.3 60.4 ± 12.5 <0.001
Age at death (%)
    20-39 years 5.1 2.4 10.1 5.6
    40-59 years 40.1 34.7 50.9 41.3
    ≥60 years 54.8 63.0 39.0 53.1 <0.001
Geographical region (%)
    West 51.7 33.6 59.2 50.2
    East 15.9 19.9 18.3 17.0
    Central 32.4 46.5 22.4 32.8 <0.001
Data are presented as mean ± SD or percentages. aThe study included deaths due to hepatitis C virus during the period 2004–2017. 
bThe p-value was calculated with the Chi-square and the one-way ANOVA tests, with the null hypothesis being no differences 
among the three health institutions. 
Figure 1 - Mortality due to hepatitis C virus in adults aged 20 
and over, according to the Health Institution (Mexican Institute 
of Social Security, Institute of Social Security for State Workers, 
Ministry of Health, or all the three Health Institutions) from 2004 
to 2017. Adjusted mortality rates per 100,000 affiliates are 
shown. The Ministry of Health included the Popular Insurance 
affiliates only.
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mortality have been decreasing in the last decades due to 
improvements in the health care safety9,10. However, in 
many middle and low-income countries, the existence of 
a large amount of cases that acquired HCV due to unsafe 
health-care procedures or due to intravenous drugs use and 
contamination that took place by the end of the 20th century, 
may increase the HCV complications and mortality in the 
coming years11.
Previous studies in Mexico have shown that blood 
transfusion is the most frequent HCV transmission 
mechanism3,12 and that HCV incidence and mortality 
rates had a mild increment in the past13,14. In this study, 
using administrative registers of the three main Health 
Institutions, which covers about 90% of the Mexican 
population with an overlapping coverage below 2%15; 
we found a continuous decrease of HCV mortality and 
hospitalization rates during the 13-year period. We have 
also found that rates were higher in women, in older age 
groups and in the West and Central regions of the country. In 
addition, in-hospital survival was 89.3%; older age groups 
and Ministry of Health hospitalizations showed lower all-
cause in-hospital survival.
Consistent with our results, a previous study of viral 
hepatitis in Mexico conducted by Mendez, found higher 
mortality rates in females, in the North, Central and West 
regions and in more aged groups14. This report has also 
observed an increase in overall mortality rates with a 
similar mortality rate curve during the period 2004-2007. 
Table 2 - Characteristics of the hospitalizations due to hepatitis C virusa.
Characteristic Mexican Institute 
of Social Security
Institute of Social 
Security for State 
Workers
Ministry of 
Health
All the three 
Institutions P-value
b
No. of hospitalizations 6,838 1,380 784 9,002
Sex (%)
    Male 41.1 31.6 57.0 41.0
    Female 58.9 68.4 43.0 59.0 <0.001
Age at hospitalization, years 
(mean ± SD) 52 ± 13.4 55.3 ± 13.1 49.4 ± 14 52.3 ± 13.5 <0.001
Age at hospitalization (%)
    20-39 years 18.2 9.9 25.8 17.6
    40-59 years 53.0 52.5 51.7 52.8
    ≥60 years 28.8 37.7 22.6 29.6 <0.001
Geographical region (%)
    West 39.4 29.6 67.3 40.3
    East 19.9 16.1 26.4 19.9
    Central 40.8 54.3 6.3 39.8 <0.001
Length of hospital stay, days 
(mean ± SD) 5 ± 6.1 5.7 ± 6.7 6.5 ± 6.5 5.3 ± 6.2 <0.001
Data are presented as mean ± SD or percentages. aThe study included hospitalizations due to hepatitis C virus during the period 
2004–2017. bThe p-value was calculated with the Chi-square and the one-way ANOVA tests, with the null hypothesis being no 
difference among the three Health Institutions. 
Figure 2 - Hospitalization due to hepatitis C virus rate in adults 
aged 20 and over, according to the Health Institution from 2004 
to 2017. Adjusted hospitalization rates per 100,000 affiliates are 
shown. The Ministry of Health included the Popular Insurance 
affiliates only.
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Contrary to these agreements, the mortality rates observed 
in our report were lower compared to those from some 
other studies carried out outside of Mexico, which reported 
stable or increasing trends, and higher mortality rates in 
males16-18. As previously mentioned, most HCV cases in 
Mexico occurred in women infected by blood transfusions, 
so that differences regarding mortality rates and the male 
predominance could be explained by transmission through 
Table 3 - Hazard ratios for all-cause in hospital mortalitya. 
Characteristic No. of hospitalizations
No. of in 
hospital 
deaths
Person-days 
of hospital 
stay
All-cause mortality 
rate (95% CI)b HR (95% CI)
Adjusted HR 
(95% CI)
No. of hospitalizations 9,002 966 47,472 20.35 (0.65-19.07)
Sex
    Female 5,312 557 27,612 20.17 (0.85-18.52) 1.00 1.00
    Male 3,690 409 19,860 20.59 (1.02-18.64) 1.02 (0.90-1.16) 1.11 (0.97-1.27)
Age at hospitalization
    20-39 years 1,585 81 7,347 11.02 (1.22-8.75) 1.00 1.00
    40-59 years 4,753 422 24,486 17.23 (0.84-15.61) 1.56 (1.23-1.98) 1.67 (1.31-2.12)
    ≥60 years 2,664 463 15,639 29.61 (1.38-26.94) 2.69 (2.12-3.40) 3.02 (2.37-3.84)
Geographical region
    Central 3,587 297 18,774 15.82 (0.92-14.06) 1.00 1.00
    West 3,628 439 19,714 22.27 (1.06-20.22) 1.41 (1.21-1.63) 1.34 (1.15-1.56)
    East 1,787 230 8,984 25.60 (1.69-22.38) 1.62 (1.36-1.92) 1.57 (1.31-1.87)
Health Institution
    Mexican Institute of 
    Social Security 6,838 639 34,477 18.53 (0.73-17.11) 1.00 1.00
     Institute of Social Security 
    for State Workers 1,380 163 7,922 20.58 (1.61-17.53) 1.11 (0.93-1.32) 1.06 (0.89-1.27)
    Ministry of Health 784 164 5,073 32.33 (2.52-27.54) 1.74 (1.47-2.07) 1.69 (1.41-2.02)
aHazard ratios (HR) were adjusted using a Cox proportional hazard model. bAll-cause mortality rates are expressed as number of 
in-hospital deaths/1,000 person-days of hospital stay. CI indicates the confidence interval.
Figure 3 - Hospitalization due to hepatitis C virus survival according to the Health Institution from 2004 to 2017 (log-rank test 
p = 5.0 × 10−9). Survival curves and their 95% Confidence Interval (CI) are shown. The Ministry of Health included the Popular 
Insurance affiliates only.
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unsafe intravenous drugs injections, which tends to increase 
and affect the male group predominantly19,20.
Only a few studies have focused on hospitalizations 
due to HCV. Similar to our results, a report from Poland 
found considerable differences among provinces and a 
slightly decrease in the percentage of hospitalized cases21. A 
second study from England, reported higher hospitalization 
rates in males during the 1989-2003 period22. In relation 
to in-hospital survival, the death frequency in our study 
(10.7%) was almost double the mortality reported in HCV 
patients without sustained viral response23. This important 
difference could be attributed to a more advanced stage 
and complexity of hospitalized HCV patients compared to 
those of HCV out-patients. One of the notorious findings 
of our study was the higher mortality and hospitalization 
rates among women (Supplementary Figures 2A and 3B). 
This finding could be explained by a female predominance 
among the HCV-infected patients included in the present 
study. However, the similarity of in-hospital mortality 
showed by our results between the sex groups might indicate 
that there are no differences between treatment and severity 
of HCV in females compared to males. This last finding 
is an interesting topic that could be addressed by future 
investigations.
Our study found a decrease in HCV death and 
hospitalization rates and differences in sex and age 
distributions among Health Institutions. In this regard, it is 
important to remark that blood screening in Mexico started 
in 1993 and nowadays about 95% of blood products are 
screened for HCV24. The control of this historical key factor 
in Mexico could explain the important reduction in both, the 
HCV prevalence among blood donors (from 0.72 in 2000 to 
0.48 in 2015)25,26 and in the HCV death and hospitalization 
rates. It is also important to note that the decrease in the 
HCV rates was inversely correlated with the increase in the 
affiliated population. The Mexican population growth and 
the increment in the health insurance coverage have caused 
a continuous rise in the number of affiliates to the Mexican 
Health Institutions in the last years27. Despite these findings, 
MoH affiliates showed a male predominance with lower 
age of disease presentation, and even an increase in HCV 
hospitalization rates compared to those of the other Health 
Institution. This last situation could suggest that different 
transmission mechanisms other than the traditional blood 
transfusion are affecting MoH affiliates.
As the study was based on the analysis of administrative 
databases, the main limitation of this report was the absence 
of relevant clinical information such as the diagnosis of 
hepatitis B virus/HIV coinfections, HCV treatment, liver 
functional condition or hepatic causes related to in-hospital 
mortality. Moreover, the presence of a single cause of 
hospitalization/death in the available registers could lead to 
underestimation of the HCV burden, because HCV usually 
appears as a contributing cause rather than the main reason 
of death or hospitalization. 
Despite the above mentioned limitations, the 
available administrative data allowed us to perform a 
significant sample-size national-wide HCV mortality and 
hospitalization analysis including the three main Health 
Institutions and all the regions of Mexico, over a 13-years 
period.
To our knowledge, this is the first analysis examining 
hospitalizations and mortality due to HCV that compared 
the three main healthcare institutions in Mexico. In spite 
of the decrease of HCV burden showed by our study, it 
is important to strength preventive and medical control 
interventions in order to eliminate viral hepatitis C as a 
public health threat in the near future.
CONCLUSION
In conclusion, the mortality and hospitalizations rates 
found in our study reflect a decrease in the burden of HCV 
in Mexico.
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